Jiangsu Ab&B Bio-Tech

Jiangsu Ab&B Bio-Tech is a clinical-stage biotechnology company headquartered in Changzhou, China, focused on the discovery and development of innovative protein degradation therapies. The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) platform to address high-unmet-need indications in oncology and metabolic diseases. Its lead candidate, AB-001, is an orally bioavailable androgen receptor degrader currently being evaluated for the treatment of metastatic castration-resistant prostate cancer. By targeting the degradation of disease-causing proteins rather than just inhibiting them, Ab&B Bio-Tech aims to overcome resistance mechanisms common in traditional therapies. The company continues to expand its pipeline with additional degraders targeting the estrogen receptor and other oncogenic drivers.